Cargando…
Translational and pharmacokinetic‐pharmacodynamic application for the clinical development of GDC‐0334, a novel TRPA1 inhibitor
GDC‐0334 is a novel small molecule inhibitor of transient receptor potential cation channel member A1 (TRPA1), a promising therapeutic target for many nervous system and respiratory diseases. The pharmacokinetic (PK) profile and pharmacodynamic (PD) effects of GDC‐0334 were evaluated in this first‐i...
Autores principales: | Chan, Phyllis, Ding, Han Ting, Liederer, Bianca M., Mao, Jialin, Belloni, Paula, Chen, Liuxi, Gao, Simon S., Joseph, Victory, Yang, Xiaoying, Lin, Joseph S., Mitra, Mayur S., Putnam, Wendy S., Quartino, Angelica, Bauer, Rebecca N., Pan, Lin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8504827/ https://www.ncbi.nlm.nih.gov/pubmed/34058071 http://dx.doi.org/10.1111/cts.13049 |
Ejemplares similares
-
First‐in‐human phase 1 trial evaluating safety, pharmacokinetics, and pharmacodynamics of NLRP3 inflammasome inhibitor, GDC‐2394, in healthy volunteers
por: Tang, Fei, et al.
Publicado: (2023) -
GDC respond to crisis
Publicado: (2020) -
Mentoring, performance and the GDC
por: Saw, Mabel, et al.
Publicado: (2021) -
Pharmacokinetics and pharmacodynamic effect of crenezumab on plasma and cerebrospinal fluid beta-amyloid in patients with mild-to-moderate Alzheimer’s disease
por: Yoshida, Kenta, et al.
Publicado: (2020) -
GDC announces new chair
Publicado: (2021)